|
[1] Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 2003,21(14):2787-2799.
[2] Assenat E, Desseigne F, Thezenas S, et al. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist, 2011,16(11):1557-1564.
[3] Bonner J A, Harari P M, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 2010,11(1):21-28.
[4] Asai H, Shinozaki E, Nozaki A, et al. Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the treatment of unresectable metastatic colorectal cancer. Gan To Kagaku Ryoho, 2011,38(8):1285-1291.
[5] Oliveras-Ferraros C, Vazquez-Martin A, Queralt B, et al. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol, 2011,39(6):1455-1479.
[6] Thienelt C D, Bunn P A, Hanna Jr N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol, 2005,23(34):8786-8793.
[7] Kim G P, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics, 2008,2(2):223-228.
[8] Douillard J Y, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 2010,28(31):4697-4705.
[9] Peeters M, Price T J, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010,28(31): 4706-4713.
[10] Schrag D, Chung K Y, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst, 2005,97(16):1221-1224.
[11] Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009,361(10):958-967.
[12] Riely G J, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res, 2006,12(3 Pt 1):839-844.
[13] Yun C H, Mengwasser K E, Toms A V, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A, 2008,105(6):2070-2075.
[14] Douillard J Y, Shepherd F A, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol, 2010,28(5): 744-752.
[15] Fukuoka M, Wu Y L, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011,29(21):2866-2874.
[16] Wu J Y, Yu C J, Shih J Y, et al. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer, 2010,67(3):348-354.
[17] Becker A, van Wijk A, Smit E F, et al. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol, 2010,5(9): 1477-1480.
[18] Xia W, Mullin R J, Keith B R, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene, 2002,21(41): 6255-6263.
[19] Geyer C E, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 2006,355(26): 2733-2743.
[20] Moy B, Goss P E. Lapatinib-associated toxicity and practical management recommendations. Oncologist, 2007,12(7): 756-765.
[21] Wang H, Shi B, Zhang Q, et al. Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. Faseb J, 2011,26(1):73-80.
[22] Jiang H, Wang H, Tan Z, et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem, 2010,286(7):5913-5920.
[23] Wang H, Zhou M, Shi B, et al. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia, 2011,13(5):461-471.
[24] Scott A M, Lee F T, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A, 2007,104(10):4071-4076.
|
